Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VRTX |
---|---|---|
09:32 ET | 17196 | 276.645 |
09:34 ET | 2827 | 276.53 |
09:36 ET | 8996 | 278.55 |
09:38 ET | 6596 | 279.24 |
09:39 ET | 8038 | 278.81 |
09:41 ET | 25365 | 278.0401 |
09:43 ET | 850 | 278.2129 |
09:45 ET | 2959 | 278.12 |
09:48 ET | 4252 | 277.79 |
09:50 ET | 2045 | 277.495 |
09:52 ET | 4945 | 278.29 |
09:54 ET | 1899 | 278.54 |
09:56 ET | 2015 | 277.845 |
09:57 ET | 3400 | 279.215 |
09:59 ET | 3663 | 279.115 |
10:01 ET | 12593 | 279.405 |
10:03 ET | 11459 | 279.04 |
10:06 ET | 14559 | 278.385 |
10:08 ET | 2780 | 277.96 |
10:10 ET | 4868 | 278.69 |
10:12 ET | 500 | 279.08 |
10:14 ET | 1615 | 279.2 |
10:15 ET | 1700 | 278.935 |
10:17 ET | 986 | 278.35 |
10:19 ET | 1271 | 278.67 |
10:21 ET | 2300 | 278.575 |
10:24 ET | 3100 | 278.48 |
10:26 ET | 1870 | 278.685 |
10:28 ET | 1050 | 278.615 |
10:30 ET | 2365 | 278.942 |
10:32 ET | 4400 | 280.28 |
10:33 ET | 2027 | 279.87 |
10:35 ET | 2660 | 279.97 |
10:37 ET | 5874 | 279.41 |
10:39 ET | 3228 | 279.63 |
10:42 ET | 500 | 280.21 |
10:44 ET | 4300 | 280.395 |
10:46 ET | 1600 | 280.77 |
10:48 ET | 4900 | 280.74 |
10:50 ET | 1400 | 280.665 |
10:51 ET | 923 | 281.09 |
10:53 ET | 1651 | 280.435 |
10:55 ET | 2470 | 280.37 |
10:57 ET | 1551 | 280.46 |
11:00 ET | 2132 | 280.245 |
11:02 ET | 3500 | 280.385 |
11:04 ET | 1610 | 280.14 |
11:06 ET | 913 | 280.23 |
11:08 ET | 1375 | 280.26 |
11:09 ET | 2463 | 280.46 |
11:11 ET | 800 | 280.345 |
11:13 ET | 2602 | 280.305 |
11:15 ET | 2730 | 280.23 |
11:18 ET | 2898 | 280.46 |
11:20 ET | 2616 | 280.325 |
11:22 ET | 1100 | 280.255 |
11:24 ET | 1778 | 279.505 |
11:26 ET | 9254 | 280.235 |
11:27 ET | 3428 | 280.62 |
11:29 ET | 1780 | 280.55 |
11:31 ET | 2325 | 280.075 |
11:33 ET | 1065 | 280.41 |
11:36 ET | 900 | 280.71 |
11:38 ET | 1100 | 281.177 |
11:40 ET | 550 | 281.1 |
11:42 ET | 6255 | 281.39 |
11:44 ET | 1900 | 281.685 |
11:45 ET | 3824 | 281.735 |
11:47 ET | 1107 | 281.69 |
11:49 ET | 1800 | 281.67 |
11:51 ET | 1050 | 281.8 |
11:54 ET | 3977 | 281.78 |
11:56 ET | 1632 | 281.84 |
11:58 ET | 1400 | 281.585 |
12:00 ET | 3196 | 281.305 |
12:02 ET | 2032 | 281.18 |
12:03 ET | 2000 | 281.11 |
12:05 ET | 1325 | 281.4223 |
12:07 ET | 1200 | 281.72 |
12:09 ET | 4058 | 282.052 |
12:12 ET | 4001 | 281.754 |
12:14 ET | 1700 | 281.56 |
12:16 ET | 3000 | 281.55 |
12:18 ET | 2204 | 280.96 |
12:20 ET | 9900 | 280.97 |
12:21 ET | 3200 | 280.9647 |
12:23 ET | 3900 | 280.68 |
12:25 ET | 2308 | 280.29 |
12:27 ET | 3676 | 280.01 |
12:30 ET | 6220 | 280.08 |
12:32 ET | 1200 | 280.205 |
12:34 ET | 1117 | 280.305 |
12:36 ET | 700 | 280.47 |
12:38 ET | 3400 | 280.5589 |
12:39 ET | 3300 | 280.9 |
12:41 ET | 1100 | 280.925 |
12:43 ET | 3947 | 281.12 |
12:45 ET | 2399 | 281.405 |
12:48 ET | 3050 | 281.08 |
12:50 ET | 1329 | 280.925 |
12:52 ET | 500 | 280.73 |
12:54 ET | 1100 | 280.79 |
12:56 ET | 300 | 280.649 |
12:57 ET | 4981 | 280.93 |
12:59 ET | 2187 | 281.2025 |
01:01 ET | 1700 | 281.4431 |
01:03 ET | 1750 | 281.235 |
01:06 ET | 1300 | 280.83 |
01:08 ET | 3444 | 280.82 |
01:10 ET | 1800 | 281.17 |
01:12 ET | 2511 | 280.78 |
01:14 ET | 1100 | 280.525 |
01:15 ET | 1765 | 280.53 |
01:17 ET | 2105 | 280.55 |
01:19 ET | 1300 | 280.505 |
01:21 ET | 700 | 280.59 |
01:24 ET | 880 | 280.5036 |
01:26 ET | 3500 | 280.6 |
01:28 ET | 1859 | 280.74 |
01:30 ET | 1215 | 281.06 |
01:32 ET | 1298 | 280.84 |
01:33 ET | 705 | 280.63 |
01:35 ET | 2496 | 280.64 |
01:37 ET | 8787 | 280.01 |
01:39 ET | 7853 | 279.7 |
01:42 ET | 2100 | 279.7 |
01:44 ET | 1320 | 279.87 |
01:46 ET | 4564 | 279.74 |
01:48 ET | 14860 | 279.65 |
01:50 ET | 1300 | 279.72 |
01:51 ET | 4138 | 280.015 |
01:53 ET | 2884 | 279.87 |
01:55 ET | 4858 | 279.84 |
01:57 ET | 7388 | 279.85 |
02:00 ET | 4237 | 279.84 |
02:02 ET | 6929 | 279.93 |
02:04 ET | 6083 | 280.21 |
02:06 ET | 6232 | 280.05 |
02:08 ET | 1897 | 279.97 |
02:09 ET | 2740 | 279.985 |
02:11 ET | 712 | 279.99 |
02:13 ET | 3824 | 280.1395 |
02:15 ET | 3410 | 279.92 |
02:18 ET | 800 | 279.97 |
02:20 ET | 1126 | 279.73 |
02:22 ET | 970 | 279.55 |
02:24 ET | 1300 | 279.4 |
02:26 ET | 600 | 279.265 |
02:27 ET | 5074 | 279.08 |
02:29 ET | 3297 | 278.93 |
02:31 ET | 800 | 278.6 |
02:33 ET | 2059 | 278.71 |
02:36 ET | 600 | 278.61 |
02:38 ET | 300 | 278.69 |
02:40 ET | 700 | 278.74 |
02:42 ET | 700 | 278.625 |
02:44 ET | 4756 | 279 |
02:45 ET | 1295 | 278.77 |
02:47 ET | 1100 | 278.79 |
02:49 ET | 6200 | 279.01 |
02:51 ET | 1000 | 279 |
02:54 ET | 696 | 278.86 |
02:56 ET | 4324 | 279.035 |
02:58 ET | 998 | 279.09 |
03:00 ET | 1000 | 279.1 |
03:02 ET | 1000 | 278.79 |
03:03 ET | 958 | 278.74 |
03:05 ET | 592 | 279.05 |
03:07 ET | 1182 | 278.83 |
03:09 ET | 1353 | 279.09 |
03:12 ET | 600 | 278.84 |
03:14 ET | 300 | 278.92 |
03:16 ET | 1348 | 278.89 |
03:18 ET | 1900 | 279.04 |
03:20 ET | 1100 | 278.77 |
03:21 ET | 1800 | 278.97 |
03:23 ET | 500 | 278.73 |
03:25 ET | 1525 | 278.73 |
03:27 ET | 400 | 278.97 |
03:30 ET | 3408 | 279.22 |
03:32 ET | 1623 | 278.795 |
03:34 ET | 2360 | 278.82 |
03:36 ET | 3339 | 278.405 |
03:38 ET | 1400 | 278.31 |
03:39 ET | 2200 | 278.27 |
03:41 ET | 3349 | 278.48 |
03:43 ET | 4934 | 278.94 |
03:45 ET | 10714 | 278.96 |
03:48 ET | 2761 | 278.75 |
03:50 ET | 4450 | 278.92 |
03:52 ET | 15144 | 279.15 |
03:54 ET | 11800 | 278.75 |
03:56 ET | 21149 | 279.65 |
03:57 ET | 26315 | 279.85 |
03:59 ET | 243836 | 280.35 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Vertex Pharmaceuticals Inc | 70.6B | 29.5x | --- |
Regeneron Pharmaceuticals Inc | 65.3B | 8.5x | +56.36% |
Moderna Inc | 56.6B | 4.2x | --- |
IQVIA Holdings Inc | 40.2B | 38.6x | +59.92% |
29.7B | --- | -9.28% | |
Seagen Inc | 32.9B | -47.4x | --- |
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF) and it has several ongoing clinical and research programs to advance and extend treatment of CF. The Company's marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Its four medicines are being used to treat the people with CF in North America, Europe and Australia. The Company has a pipeline of investigational therapies in other serious diseases where it is leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. The Company’s other pipeline products include CTX001, VX-147, VX-121, VX-561, VX-548, and VX-880.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $71.7B |
---|---|
Revenue (TTM) | $7.9B |
Shares Outstanding | 255.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.50 |
EPS | $9.49 |
Book Value | $39.69 |
P/E Ratio | 29.5x |
Price/Sales (TTM) | 9.0 |
Price/Cash Flow (TTM) | 27.8x |
Operating Margin | 36.93% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.